1132 - Integrated Quantitative Systems Pharmacology (QSP) Characterizing Viral Dynamics After Intramuscular (IM) Adintrevimab (ADI) Administration in Participants with Mild to Moderate Coronavirus Disease (COVID-19)

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

ET

Evan Tarbell, PhD

Enhanced Pharmacodynamics
Buffalo, New York, United States
Scott A. Van Wart, PhD

Vice President and Chief Scientific Officer
Enhanced Pharmacodynamics
Buffalo, New York, United States
MP

Myra Popejoy, PharmD

Adagio Therapeutics
Waltham, Massachusetts, United States
KN

Kristin Narayan, PhD

Adagio Therapeutics
Waltham, Massachusetts, United States
EH

Ellie Hershberger, PharmD

Adagio Therapeutics
Waltham, Massachusetts, United States
XP

Xia Pu, PhD

clinical pharmacologist
Invivyd, Inc.
Waltham, Massachusetts, United States
JG

Jean Gong, PhD

Adagio Therapeutics
Waltham, Massachusetts, United States
CR

Christopher M. Rubino, PharmD

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
AS

Andrew Santulli, BSE

Enhanced Pharmacodynamics
Buffalo, New York, United States

Paul Ambrose, PharmD

Head of Quantitative Pharmacology, Clinical Pharmacology
Adagio Therapeutics
Waltham, New York, United States